EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Glutamatergic neurotransmission: A potential pharmacotherapeutic target for the treatment of cognitive disorders

Pratik Chakraborty, Abhijit Dey, Abilash Valsala Gopalakrishnan, Kumari Swati, Shreesh Ojha, Anand Prakash, Dhruv Kumar, Rashmi K Ambasta, Niraj Kumar Jha, Saurabh Kumar Jha, Saikat Dewanjee

Ageing Research Reviews · 2023-03 · 85 · 101838

DOI: 10.1016/j.arr.2022.101838 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Ageing Research Reviews, 2023-03. Verfasst von Pratik Chakraborty und 10 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Receptors, Glutamate. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 317 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the mammalian brain, glutamate is regarded to be the primary excitatory neurotransmitter due to its widespread distribution and wide range of metabolic functions. Glutamate plays key roles in regulating neurogenesis, synaptogenesis, neurite outgrowth, and neuron survival in the brain. Ionotropic and metabotropic glutamate receptors, neurotransmitters, neurotensin, neurosteroids, and others co-ordinately formulate a complex glutamatergic network in the brain that maintains optimal excitatory neurotransmission. Cognitive activities are potentially synchronized by the glutamatergic activities in the brain via restoring synaptic plasticity. Dysfunctional glutamate receptors and other glutamatergic components are responsible for the aberrant glutamatergic activity in the brain that cause cognitive impairments, loss of synaptic plasticity, and neuronal damage. Thus, controlling the brain's glutamatergic transmission and modifying glutamate receptor function could be a potential therapeutic strategy for cognitive disorders. Certain drugs that regulate glutamate receptor activities have shown therapeutic promise in improving cognitive functions in preclinical and clinical studies. However, several issues regarding precise functional information of glutamatergic activity are yet to be comprehensively understood. The present article discusses the scope of developing glutamatergic systems as prospective pharmacotherapeutic targets to treat cognitive disorders. Special attention has been given to recent developments, challenges, and future prospects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cognitive DysfunctionReceptors, GlutamateHumansGlutamic AcidProspective StudiesSynaptic Transmission

Stichwörter der Autor:innen

BrainCognitive DisordersExcitotoxicityGlutamatergic signalingTherapeutic interventions

Substanzen

Glutamic AcidReceptors, Glutamate

Autor:innen und Institutionen

  • Advanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India.
  • Department of Life Sciences, Presidency University, Kolkata 700073, West Bengal, India.
  • Department of Biomedical Sciences, School of Bio Sciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu 632014, India.
  • Department of Biotechnology, School of Life Science, Mahatma Gandhi Central University, Motihari, Bihar, India.
  • Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, Abu Dhabi, United Arab Emirates.
  • School of Health Sciences & Technology, UPES University, Dehradun, Uttarakhand 248007, India.

Förderung

  • Council of Scientific and Industrial Research, India

Zitieren

APA

Chakraborty, P., Dey, A., Gopalakrishnan, A. V., Swati, K., Ojha, S., Prakash, A., Kumar, D., Ambasta, R. K., Jha, N. K., Jha, S. K., & Dewanjee, S. (2023). Glutamatergic neurotransmission: A potential pharmacotherapeutic target for the treatment of cognitive disorders. Ageing Research Reviews, 85, 101838. https://doi.org/10.1016/j.arr.2022.101838

Vancouver

Chakraborty P, Dey A, Gopalakrishnan AV, Swati K, Ojha S, Prakash A, et al. Glutamatergic neurotransmission: A potential pharmacotherapeutic target for the treatment of cognitive disorders. Ageing Research Reviews. 2023;85:101838. doi:10.1016/j.arr.2022.101838

BibTeX
@article{Chakraborty2023,
  author = {Chakraborty, Pratik and Dey, Abhijit and Gopalakrishnan, Abilash Valsala and Swati, Kumari and Ojha, Shreesh and Prakash, Anand and Kumar, Dhruv and Ambasta, Rashmi K and Jha, Niraj Kumar and Jha, Saurabh Kumar and Dewanjee, Saikat},
  title = {Glutamatergic neurotransmission: A potential pharmacotherapeutic target for the treatment of cognitive disorders},
  journal = {Ageing Research Reviews},
  year = {2023},
  volume = {85},
  pages = {101838},
  doi = {10.1016/j.arr.2022.101838}
}
Kostenlos starten →